Navigation Links
Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
Date:10/17/2007

come infected during pregnancy.

CMV infection affects 30 to 60 percent of the patients undergoing various transplant procedures, causing transplant rejection, serious illness and even death if untreated. Expensive antiviral drug therapy is used to control the disease, but does not eliminate the infection. Congenital CMV infection affects one out of every hundred infants, and causes severe consequences in about 3,600 infants and death in about 400 each year in the United States.

There is no approved vaccine against CMV. Vaccine approaches that result in predominantly antibody responses to CMV have not proven highly effective in transplant patients. Vaccine approaches using live, attenuated viruses can induce both antibody and cellular immune responses, but pose a potential safety concern, particularly for immunocompromised patients, of causing the disease they are intended to prevent. Vical's novel DNA vaccine approach is designed to induce both antibody and cellular immune responses against specific features of the CMV virus without the risk of causing CMV disease. Vical's vaccine has received orphan drug designation for hematopoietic stem cell transplant and solid organ transplant patients.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to c
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... DALLAS and NEW YORK ... (OTCBB: ACCP), a developer of new products for oncology ... mucositis, MuGard ® , has been featured in an ... Oral Mucositis Symptoms in Head and Neck Cancers."  Dr. ... mucositis, provides insight on the growing demand seen in ...
(Date:7/30/2014)... , July 30, 2014   Medical Equipment ... have been awarded a Department of Defense (US Army) ... to supply a mobile MRI diagnostic machine and technical ... Business (WOSB) through the Small Business Administration (SBA), Medical ... the field with the latest medical diagnostic equipment. The ...
(Date:7/30/2014)... SUNNYVALE, California , July 30, 2014 /PRNewswire/ ... GPU technology and CUDA programming expertise to big ... other markets  eInfochips, a leading engineering ... to clients to develop NVIDIA GPU-powered solutions for ... , high-performance computing (HPC), industrial ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... NATICK, Mass., May 6, 2011 Boston Scientific ... the launch and first implants of its ENERGEN™ ... implantable cardioverter defibrillators (ICDs) in Europe and other ... thinnest high-energy devices to treat heart failure and ...
... BD Diagnostics, a segment of BD (Becton, Dickinson and ... launch of the BD MAX™ Open System for molecular testing, ... developed assays and offer enhanced testing services that elevate the ... the launch announcement on the opening day of the 21st ...
Cached Medicine Technology:Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 2Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 3Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 4BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 2BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 3BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 4
(Date:7/31/2014)... The study, The Truth Behind Variation in ... care payments for four clinical areas—congestive heart failure, acute ... and knees). Using the definition of episodes of ... program, the study examines these clinical areas within the ... , “Our study reaffirms that, in most instances, the ...
(Date:7/30/2014)... Riverdale, NJ (PRWEB) July 31, 2014 ... in Macy’s ninth annual national “Shop For A Cause” ... For A Cause” is a unique one-day-only shopping event ... helped raise more than $44 million for charities across ... year’s event by purchasing shopping passes from Push to ...
(Date:7/30/2014)... Dayton, Ohio (PRWEB) July 31, 2014 ... welcome Douglas A. Fecher President and CEO, Wright-Patt Credit ... , Fecher, is a foremost financial CEO with an ... vice president of lending and later chief operating officer ... 2000, Fecher has led the Beavercreek-based Wright-Patt Credit Union ...
(Date:7/30/2014)... 31, 2014 WalkingSticksandCane.com has just ... The ladies will love the new European fashions and the ... These sticks and canes are from one from one of ... of the styles re unique and offer the consumer the ... Blackthorn Walking Sticks are some of the rarest and most ...
(Date:7/30/2014)... born with severe combined immunodeficiency (SCID) can be successfully ... to experts led by Memorial Sloan Kettering,s Richard J. ... transplant protocols. Their review will be published in the ... of Medicine . , SCID is a group of ... malfunction. When this breakdown occurs, babies no longer have ...
Breaking Medicine News(10 mins):Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:European Walking Sticks from WalkingSticksandCane.com 2Health News:Transplantation shown to be highly effective in treating immune deficiency in children 2
... Despite of the significant improvements in dialysis treatments, over ... U.S. Hemodialysis International, which published the// study, finds ... malnutrition. ,Large Body Mass Combats Effects ... what has been termed the “obesity paradox,” wherein obesity ...
... health crisis triggered by the death of over 40 ... institution's laboratory, has prompted Panamanian President// Martin Torrijos to ... ,Torrijos said that the government had since closed ... Body (CSS), permanently in a bid to win back ...
... a new study, septic shock—a dangerous, often deadly runaway ... research also suggests how a drug might// temper sepsis. ... been revealed in an experimental animal. ... Sabin Professor of Microbiology and Molecular Pathogenesis at NYU ...
... grow old in good health should have strong grip, not ... recent study.// ,A 40-year study of nearly 6000 ... nine factors that were good predictors of which middle-aged men ... ,The nine factors were: not being overweight, low blood sugar ...
... women who complain of severe itching and redness of skin ... intercourse that has been now confirmed by doctors as a ... present in semen. Thankfully doctors have given the hope to ... according to the report made in LiveScience. ,The ...
... More than 80,000 people in the United States are on ... for the death of a matching donor, but more and ... ,Last year nearly 7,000 people donated a kidney, segment of ... in need of a transplant. In fact at some major ...
Cached Medicine News:Health News:New Study Finds On/Off Switch for Septic Shock 2Health News:Keys to Good Health in Old Age Begins in Midlife 2Health News:See, men cause allergies in women after sex 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 3
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Permanent, sutureless, epicardial pacing leads...
Medicine Products: